Dalidowicz, M; Miller, L. Allocations processes for operating room use. 2022 Jun 09. Document no.: EOC220602 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 31 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc501
Howell-Spooner, B. What are long COVID's demands on the healthcare system, and its severity of the illness? 2022 Jun 03, Document no.: EPM210602v003 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 22 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc494
Dalidowicz, M; Fox, L. Is there evidence that children under 18 should receive the booster to increase their immunity? 2022 Apr 06, Document no.: EOC220102v002 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 11 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc466
Howell-Spooner, B; Ellsworth, C. What are long COVID's demands on the healthcare system, and its severity of the illness? 2022 Mar 11, Document no.: EPM210602v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 64 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc460
Fox, L; Ellsworth, C. How useful is it to continue with daily symptom screening of HCW, and what are the screening policies? 2022 Feb 02, Document no.: EOC220104 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 18 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc434
Miller, L., Howell-Spooner, B. How effective are COVID-19 vaccines? 2022 Jan 14, Document no.: INF031801v020 ESR . In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 9 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc425
Young, C; Dalidowicz, M. How are rapid antigen tests being used in different settings? What is the evidence on the impact of the use of rapid antigen tests on COVID-19 outbreak parameters?? 2021 Dec 30, Document no.: EOC211203 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 115 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc417
Miller, L., Howell-Spooner, B.. What is the epidemiology of variants and what are the implications for healthcare? 2021 Dec 17, Document no.: EOC031801v020 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 43 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc410
Miller, L., Howell-Spooner, B.. What is the epidemiology of variants and what are the implications for healthcare? 2021 Dec 03, Document no.: EOC031801v019 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 39 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc406
Miller, L. Howell-Spooner, B. What is the epidemiology of variants and what are the implications for healthcare? 2021 Nov 05, Document no.: EOC031801v017 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 23 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc393
Mueller, M; Dalidowicz, M. Long COVID: What does it mean for the healthcare system and programs to? 2021 Oct 21, Document no.: EOC021901v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 70 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc386
Howell-Spooner, B., Mueller, M. What are the effects of the new COVID variants on transmission and school reopenings in pediatric populations? 2021 Aug 18, Document no.: PH030801v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 49 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc359
Ellsworth, C. What are other jurisdictions offering for incentive-based COVID-19 vaccine campaigns? 2021 Aug 17, Document no.: EOC210501v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 8 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc356
Young, C; Mueller, M. What are the causes of vaccine hesitancy? What programs/approaches have been successful in reducing vaccine hesitancy? 2021 Aug 11, Document no.: EOC012201v3 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 26 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc355
Dalidowicz, M; Mueller, M. What is the clinical management of post-acute COVID?? 2021 Jun 24, Document no.: PH210602 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 47 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc335
Dalidowicz, M; Mueller, M. What healthcare delivery models or programs have been described and implemented to address post-acute COVID? 2021 Jun 18, Document no.: PH210601 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 22 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc330
Dalidowicz, M; Fox, L. What is the risk of COVID-19 acquisition via exposures of the ocular mucosa? 2021 Mar 3; Document no.: PPE030101-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 51 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc270
Miller, L; Howell-Spooner, B. What is the risk of transmission of COVID-19 from high respiratory efforts for prolonged periods of time (>15 min) at a physical distance of 3-4 m or more? 2021 Jan 27; Document no.: PH012501-02 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 15 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc254
Miller, L; Howell-Spooner, B. What is the risk of transmission of COVID-19 from high respiratory efforts for prolonged periods of time (>15 min) at a physical distance of 3-4 m or more? 2021 Jan 26; Document no.: PH012501-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 29 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc252
Miller, L.; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 4; Document no.: EOC062201v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 46 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc232
